Health Catalyst
HCAT
162 hedge funds and large institutions have $568M invested in Health Catalyst in 2023 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 56 increasing their positions, 54 reducing their positions, and 27 closing their positions.
10% more capital invested
Capital invested by funds: $516M → $568M (+$52.5M)
4% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 54
2.11% less ownership
Funds ownership: 89.19% → 87.08% (-2.1%)
3% less funds holding
Funds holding: 167 → 162 (-5)
15% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 27
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
57% less call options, than puts
Call options by funds: $248K | Put options by funds: $572K
Top Buyers
Top Sellers
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$7.7M |
| 2 |
JP Morgan Chase
New York
|
-$6.44M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$4.97M |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
-$3.7M |
| 5 |
N
Numerai
San Francisco,
California
|
-$3.45M |
HCAT Hedge Fund Activity: Q1 2023 in Review
162 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Health Catalyst (HCAT) for Q1 2023, worth a combined $568M — up 10% from $516M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of HCAT and 23 opened new positions — a net loss of 4 holders — while 54 trimmed existing stakes and 56 added.
The largest buyer was Wellington Management Group, adding an estimated $18.7M. The largest seller was Balyasny Asset Management, cutting an estimated $7.7M.
- 162 institutional investors held Health Catalyst (HCAT) as of Q1 2023, down from 167 in Q4 2022.
- Funds reported $568M of Health Catalyst stock for Q1 2023, up 10% quarter-over-quarter.
- 23 funds opened new Health Catalyst positions in Q1 2023 and 27 closed out, a net change of -4 holders.
- The largest Health Catalyst buyer in Q1 2023 was Wellington Management Group, an estimated $18.7M added.
- The largest Health Catalyst seller in Q1 2023 was Balyasny Asset Management, an estimated $7.7M sold.
Based on aggregated 13F filings for Q1 2023.